BRNS biotech catalysts & pipeline

BARINTHUS BIOTHERAPEUTICS PLC · Data as of 2026-09-08

Upcoming catalysts

CLY-101 (Balomenib) — Topline data

H2 2026

· Phase 2A proof of principle study in Type 2 diabetes patients first top-line data readout expected the second half of 2026

Source filing

VTP-1000 — Topline data

Q4 2026

Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026.

Source filing

VTP-1000 — Conference presentation

Oct 9–Oct 14

An abstract outlining Phase 1 Single Ascending Dose data for VTP-1000 has been selected for poster presentation at the American College of Gastroenterology ("ACG") Annual Scientific Meeting, to be held October 9–14, 2026 in Nashville, Tennessee.

Source filing

Explore the free biotech catalyst calendar